MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
July 27, 2007
Brian Lawler
Jumpstarting Genzyme A great quarter for Genzyme. All three of its top products had double-digit percentage sales gains; operating margins are up too. mark for My Articles similar articles
The Motley Fool
April 26, 2007
Brian Lawler
Genzyme Is Good The biopharma giant announced unexpectedly strong first-quarter results on the back of higher sales of recently launched compounds. mark for My Articles similar articles
The Motley Fool
May 30, 2007
Brian Lawler
Genzyme Gobbles Up a Partner Another day, another biotech acquisition for drugmaker Genzyme. Investors, with more than $500 million in free cash flow last year alone, Genzyme has money to spare. mark for My Articles similar articles
The Motley Fool
September 27, 2006
Brian Lawler
Enormous Interest in AnorMED Genzyme and Millenium vie to purchase the Canadian biotech. Shares of AnorMED currently trade for more than $12 a share. mark for My Articles similar articles
The Motley Fool
September 6, 2006
Brian Lawler
AnorMED's Tumultuous Year A takeover attempt follows management shakeups at the biopharmaceutical firm. Investors, take note. mark for My Articles similar articles
The Motley Fool
May 26, 2010
Brian Orelli
Is This 4,000-Liter Bioreactor Half-Full? Or half-empty? Only time will tell for Genzyme. mark for My Articles similar articles
The Motley Fool
February 4, 2008
Brian Lawler
Genzyme Tells It Like It Is Genzyme shows some sparkle at investors' conference. Investors, take note. mark for My Articles similar articles
The Motley Fool
October 12, 2006
Brian Lawler
Genzyme Runs a Tight Ship Revenues are up at the biopharmaceutical company, but shares dropped in morning trading. mark for My Articles similar articles
The Motley Fool
July 26, 2010
Ryan McBride
How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis mark for My Articles similar articles
The Motley Fool
February 23, 2010
Brian Orelli
Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year. mark for My Articles similar articles
The Motley Fool
April 24, 2008
Brian Lawler
FDA Stings Genzyme Earnings A nasty surprise hurts the drug developer's first quarter results. mark for My Articles similar articles
The Motley Fool
September 28, 2007
Brian Lawler
Bioenvision Shareholder Battle Genzyme announces that it "cannot and will not" raise its $5.60-a-share bid for Bioenvision before shareholders go to vote on its proposed takeover. Investors, take note. mark for My Articles similar articles
The Motley Fool
July 23, 2007
Brian Lawler
Acquisitive Ways Paying Off for Genzyme A recently acquired drug yields positive study results. Genzyme investors, take note. mark for My Articles similar articles
The Motley Fool
July 12, 2006
Brian Lawler
Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share. mark for My Articles similar articles
The Motley Fool
November 14, 2007
Brian Lawler
Genzyme Zigs, Shares Zag Genzyme gets downbeat news that will delay the launch of its lead drug, but shares rise. Investors, take note. mark for My Articles similar articles
The Motley Fool
September 13, 2010
Brian Orelli
When All Else Fails, Sell! Genzyme has no other choice. mark for My Articles similar articles
The Motley Fool
March 2, 2004
David Nierengarten
Genzyme's Oncology Acquisitions The biotech gobbles up two smaller firms for their cancer treatment pipelines. mark for My Articles similar articles
The Motley Fool
July 26, 2010
Brian Orelli
Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete? mark for My Articles similar articles
The Motley Fool
October 29, 2007
Brian Lawler
Genzyme Gets It Together Genzyme may not engender as much investor excitement as Carl-Icahn-acquisition-hyped biopharmas. But its diverse pipeline, and the strong performance it delivers quarter after quarter, deserve some investor attention. mark for My Articles similar articles
The Motley Fool
November 24, 2010
Brian Orelli
Yay! We Don't Have to Pay an 18.5% Penalty Genzyme moves one step closer to a comeback. The company announced today that it had met its deadline for moving the fill-and-finish activities for drugs sold in the U.S. out of its beleaguered Allston, Mass., plant. mark for My Articles similar articles
The Motley Fool
October 10, 2007
Brian Lawler
Bioenvision Demands a Recount Bioenvision decided to hold the polls open one more day, in hopes that some stockholders who hadn't yet participated would vote for their proposed acquisition by Genzyme. mark for My Articles similar articles
The Motley Fool
November 19, 2009
Brian Orelli
This Stock Is a Train Wreck Genzyme's string of missteps has investors nervous. mark for My Articles similar articles
The Motley Fool
September 23, 2010
Ryan McBride
Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault. mark for My Articles similar articles
The Motley Fool
October 4, 2010
Ryan McBride
Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share. mark for My Articles similar articles
The Motley Fool
May 14, 2010
Ryan McBride
Genzyme in "Tough Spot" With Icahn Proxy Challenge Carl Icahn is pushing for change, but Genzyme's CEO has been pushing back. mark for My Articles similar articles
The Motley Fool
October 4, 2010
Brian Orelli
That's No Way to Make Friends Sanofi goes hostile on Genzyme. mark for My Articles similar articles
The Motley Fool
December 10, 2008
Brian Orelli
A Painless Advisory Panel Meeting Genzyme might be getting a Christmas present from the Food and Drug Administration. An FDA advisory panel unanimously recommended approval for Genzyme's osteoarthritis pain drug Synvisc-One. mark for My Articles similar articles
The Motley Fool
August 20, 2010
Brian Orelli
This Billionaire Likes Biotech. Should You? It depends on how much you trust management. mark for My Articles similar articles
The Motley Fool
October 9, 2006
Brian Lawler
Much-Needed Publicity for Millennium Millennium Pharmaceuticals' cancer-fighting drug Velcade is set to gain exposure for a new treatment. Investors, take note. mark for My Articles similar articles
The Motley Fool
August 30, 2010
Ryan McBride
Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams. mark for My Articles similar articles
BusinessWeek
March 22, 2004
Gene G. Marcial
Look Who May Be Courting Bioenvision Genzyme may be interested in Bioenvision as well. Why? In 2001, Bioenvision licensed to ILEX the right to co-develop and market in the U.S. and Canada its Clorfarabine, a drug for leukemia. Bioenvision still holds the rights outside North America. The company will soon file for Food & Drug Administration approval of Clorfarabine, which has a $1 billion market potential. mark for My Articles similar articles
The Motley Fool
July 18, 2005
Stephen D. Simpson
Rare Diseases Mean Solid Growth for Genzyme Genzyme doesn't target well-known diseases, but then neither does the competition. Valuing these shares is a bit tricky. mark for My Articles similar articles
The Motley Fool
July 7, 2010
Brian Orelli
That's Gotta Hurt: Recommending the Competition Supply constraints continue to plague Genzyme. mark for My Articles similar articles
The Motley Fool
February 17, 2010
Brian Orelli
Execute Well or You're Out Genzyme needs to show investors that it can rebuild. mark for My Articles similar articles
The Motley Fool
September 11, 2010
Luke Timmerman
Genzyme Cutting 1,000 Jobs Over Next 15 Months The biotech powerhouse has had a tough stretch of late, and now it says it must lay off some of its workforce. mark for My Articles similar articles
The Motley Fool
March 3, 2011
Ryan McBride
With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players. mark for My Articles similar articles
The Motley Fool
April 8, 2010
Brian Orelli
Is Icahn Stuck in the Station? Saving Genzyme's train wreck may be difficult. mark for My Articles similar articles
BusinessWeek
June 4, 2007
Gene G. Marcial
What Big Investors See In Bioenvision Bioenvision has attracted big investors. mark for My Articles similar articles
The Motley Fool
June 16, 2010
Ryan McBride
Genzyme Annual Meeting Remarkably Mundane, Despite Rocky Year Genzyme's annual meeting was over in about an hour, and although the company took some hard questions from a shareholder, it appears that chairman and CEO Henri Termeer and the rest of the company's directors were easily reelected to serve on the board of directors. mark for My Articles similar articles
The Motley Fool
June 15, 2010
Ryan McBride
Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week. mark for My Articles similar articles
The Motley Fool
February 3, 2010
Brian Orelli
Pfizer's Hedge Pays Off FDA wants more data from Pfizer's partner, Protalix on their treatment for Gaucher disease. mark for My Articles similar articles
The Motley Fool
January 5, 2010
Brian Orelli
A Deal Manufactured by Necessity Genzyme gets some help from a new friend. mark for My Articles similar articles
The Motley Fool
April 16, 2004
Charly Travers
Genzyme's Minor Disappointment The latest sales figures for Genzyme's newest drug, Aldurazyme, show that a potential growth-driving drug may be stalling out. mark for My Articles similar articles
The Motley Fool
June 10, 2010
Brian Orelli
Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday. mark for My Articles similar articles
The Motley Fool
November 18, 2010
Brian Orelli
Genzyme: Slimmed Down, Gussied Up But will anyone buy it? mark for My Articles similar articles
The Motley Fool
December 13, 2010
Brian Orelli
Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price. mark for My Articles similar articles
The Motley Fool
July 23, 2009
Brian Orelli
This Too Shall Pass ... Like a Kidney Stone Demand outstrips supply? Boo-hoo. Lowered guidance because a company can't make enough to keep up with demand. Example: Genzyme mark for My Articles similar articles
The Motley Fool
October 21, 2010
Brian Orelli
Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track. mark for My Articles similar articles
BusinessWeek
May 2, 2005
Gene G. Marcial
What Other Biotechs See In Bioenvision Bioenvision's childhood leukemia drug Clofarabine has received FDA approval and is expected to increase the profitability of the drug maker. mark for My Articles similar articles
The Motley Fool
August 30, 2010
Brian Orelli
Shocker: Sanofi's Interested in Genzyme But there are a lot of reason for Genzyme's management to shun the bid. Will it come to fruition? mark for My Articles similar articles